PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing targeted therapies for p53 mutations, the most frequently mutated gene in human cancers. Headquartered in Cranbury, New Jersey, the company leverages its proprietary structure-based drug discovery platform to design small molecule therapies that restore wild-type, or normal, p53 function to cancer cells. The company's lead product candidate, PC14586, is a first-in-class, orally bioavailable small molecule designed to selectively target a specific p53 mutation (Y220C) and is currently being evaluated in clinical trials for patients with locally advanced or metastatic solid tumors. PMV Pharmaceuticals also advances additional programs targeting other p53 mutations, including PC14586 analogs and next-generation compounds aimed at different hotspot mutations. The company operates as a clinical-stage biopharmaceutical organization with no commercial products currently on the market, relying on capital raises and strategic partnerships to fund its research and development activities. Founded in 2013 and having completed its initial public offering in 2020, PMV Pharmaceuticals collaborates with leading academic institutions and cancer research centers to advance its pipeline. The company's approach addresses a significant unmet medical need, as approximately 50% of all cancers harbor p53 mutations, representing a substantial patient population with limited treatment options.